Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 4;25(23):13053.
doi: 10.3390/ijms252313053.

Different Therapeutic Approaches for Dry and Wet AMD

Affiliations
Review

Different Therapeutic Approaches for Dry and Wet AMD

Nicoletta Marchesi et al. Int J Mol Sci. .

Abstract

Age-related macular degeneration (AMD) is the most common cause of irreversible loss of central vision in elderly subjects, affecting men and women equally. It is a degenerative pathology that causes progressive damage to the macula, the central and most vital part of the retina. There are two forms of AMD depending on how the macula is damaged, dry AMD and wet or neovascular AMD. Dry AMD is the most common form; waste materials accumulate under the retina as old cells die, not being replaced. Wet AMD is less common, but can lead to vision loss much more quickly. Wet AMD is characterized by new abnormal blood vessels developing under the macula, where they do not normally grow. This frequently occurs in patients who already have dry AMD, as new blood vessels are developed to try to solve the problem. It is not known what causes AMD to develop; however, certain risk factors (i.e., age, smoking, genetic factors) can increase the risk of developing AMD. There are currently no treatments for dry AMD. There is evidence that not smoking, exercising regularly, eating nutritious food, and taking certain supplements can reduce the risk of acquiring AMD or slow its development. The main treatment for wet AMD is inhibitors of VEGF (vascular endothelial growth factor), a protein that stimulates the growth of new blood vessels. VEGF inhibitors can stop the growth of new blood vessels, preventing further damage to the macula and vision loss. In most patients, VEGF inhibitors can improve vision if macular degeneration is diagnosed early and treated accordingly. However, VEGF inhibitors cannot repair damage that has already occurred. Current AMD research is trying to find treatments for dry AMD and other options for wet AMD. This review provides a summary of the current evidence regarding the different treatments aimed at both forms of AMD with particular and greater attention to the dry form.

Keywords: anti-VEGF; dietary supplements; dry AMD; neurodegenerative disease; wet AMD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main AMD treatments. The purple section illustrates the treatments for dry AMD, whereas the red section depicts the treatments for wet AMD. The treatments that are not related to either form are summarized in the central area in blue. This figure has been created by the authors using Canva and Smart—Servier Medical Art.

References

    1. Thomas C.J., Mirza R.G., Gill M.K. Age-Related Macular Degeneration. Med. Clin. North. Am. 2021;105:473–491. doi: 10.1016/j.mcna.2021.01.003. - DOI - PubMed
    1. Fleckenstein M., Keenan T.D.L., Guymer R.H., Chakravarthy U., Schmitz-Valckenberg S., Klaver C.C., Wong W.T., Chew E.Y. Age-Related Macular Degeneration. Nat. Rev. Dis. Primers. 2021;7:31. doi: 10.1038/s41572-021-00265-2. - DOI - PubMed
    1. Fleckenstein M., Schmitz-Valckenberg S., Chakravarthy U. Age-Related Macular Degeneration: A Review. JAMA. 2024;331:147–157. doi: 10.1001/jama.2023.26074. - DOI - PubMed
    1. Ferris F.L., Wilkinson C.P., Bird A., Chakravarthy U., Chew E., Csaky K., Sadda S.R. Clinical Classification of Age-Related Macular Degeneration. Ophthalmology. 2013;120:844–851. doi: 10.1016/j.ophtha.2012.10.036. - DOI - PMC - PubMed
    1. Flores R., Carneiro Â., Vieira M., Tenreiro S., Seabra M.C. Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives. Ophthalmologica. 2021;244:495–511. doi: 10.1159/000517520. - DOI - PubMed

MeSH terms

Substances

Grants and funding

LinkOut - more resources